

FIRST REGULAR SESSION

# HOUSE BILL NO. 1170

## 98TH GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVE REHDER.

2502H.011

D. ADAM CRUMBLISS, Chief Clerk

### AN ACT

To repeal section 195.017 as enacted by senate bill no. 491, ninety-seventh general assembly, second regular session, and to enact in lieu thereof one new section relating to schedules of controlled substances.

*Be it enacted by the General Assembly of the state of Missouri, as follows:*

Section A. Section 195.017 as enacted by senate bill no. 491, ninety-seventh general assembly, second regular session, is repealed and one new section enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

- (1) Has high potential for abuse; and
- (2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

- (1) The controlled substances listed in this subsection are included in Schedule I;
- (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

- (a) Acetyl-alpha-methylfentanyl;
- (b) Acetylmethadol;
- (c) Allylprodine;
- (d) Alphacetylmethadol;
- (e) Alphameprodine;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

- 16 (f) Alphamethadol;
- 17 (g) Alpha-methylfentanyl;
- 18 (h) Alpha-methylthiofentanyl;
- 19 (i) Benzethidine;
- 20 (j) Betacetylmethadol;
- 21 (k) Beta-hydroxyfentanyl;
- 22 (l) Beta-hydroxy-3-methylfentanyl;
- 23 (m) Betameprodine;
- 24 (n) Betamethadol;
- 25 (o) Betaprodine;
- 26 (p) Clonitazene;
- 27 (q) Dextromoramide;
- 28 (r) Diampromide;
- 29 (s) Diethylthiambutene;
- 30 (t) Difenoxyin;
- 31 (u) Dimenoxadol;
- 32 (v) Dimepheptanol;
- 33 (w) Dimethylthiambutene;
- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etoxidine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacetylmorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;
- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;

52 (pp) Para-fluorofentanyl;

53 (qq) PEPAP;

54 (rr) Phenadoxone;

55 (ss) Phenampromide;

56 (tt) Phenomorphan;

57 (uu) Phenoperidine;

58 (vv) Piritramide;

59 (ww) Proheptazine;

60 (xx) Properidine;

61 (yy) Propiram;

62 (zz) Racemoramide;

63 (aaa) Thiofentanyl;

64 (bbb) Tilidine;

65 (ccc) Trimeperidine;

66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers  
67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers  
68 is possible within the specific chemical designation:

69 (a) Acetorphine;

70 (b) Acetyldihydrocodeine;

71 (c) Benzylmorphine;

72 (d) Codeine methylbromide;

73 (e) Codeine-N-Oxide;

74 (f) Cyprenorphine;

75 (g) Desomorphine;

76 (h) Dihydromorphine;

77 (i) Drotebanol;

78 (j) Etorphine (except hydrochloride salt);

79 (k) Heroin;

80 (l) Hydromorphenol;

81 (m) Methyldesorphine;

82 (n) Methyldihydromorphine;

83 (o) Morphine methylbromide;

84 (p) Morphine methylsulfonate;

85 (q) Morphine-N-Oxide;

86 (r) Myorphine;

87 (s) Nicocodeine;

- 88 (t) Nicomorphine;  
89 (u) Normorphine;  
90 (v) Pholcodine;  
91 (w) Thebacon;  
92 (4) Any material, compound, mixture or preparation which contains any quantity of the  
93 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically  
94 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within  
95 the specific chemical designation:  
96 (a) 4-bromo-2, 5-dimethoxyamphetamine;  
97 (b) 4-bromo-2, 5-dimethoxyphenethylamine;  
98 (c) 2,5-dimethoxyamphetamine;  
99 (d) 2,5-dimethoxy-4-ethylamphetamine;  
100 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;  
101 (f) 4-methoxyamphetamine;  
102 (g) 5-methoxy-3,4-methylenedioxyamphetamine;  
103 (h) 4-methyl-2, 5-dimethoxyamphetamine;  
104 (i) 3,4-methylenedioxyamphetamine;  
105 (j) 3,4-methylenedioxymethamphetamine;  
106 (k) 3,4-methylenedioxy-N-ethylamphetamine;  
107 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;  
108 (m) 3,4,5-trimethoxyamphetamine;  
109 (n) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its isomers, salts, and salts of  
110 isomers;  
111 (o) Alpha-ethyltryptamine;  
112 (p) Alpha-methyltryptamine;  
113 (q) Bufotenine;  
114 (r) Diethyltryptamine;  
115 (s) Dimethyltryptamine;  
116 (t) 5-methoxy-N,N-diisopropyltryptamine;  
117 (u) Ibogaine;  
118 (v) Lysergic acid diethylamide;  
119 (w) Marijuana or marihuana;  
120 (x) Mescaline;  
121 (y) Parahexyl;  
122 (z) Peyote, to include all parts of the plant presently classified botanically as *Lophophora*  
123 *Williamsii* Lemaire, whether growing or not; the seeds thereof; any extract from any part of such

- 124 plant; and every compound, manufacture, salt, derivative, mixture or preparation of the plant,  
125 its seed or extracts;
- 126 (aa) N-ethyl-3-piperidyl benzilate;  
127 (bb) N-methyl-3-piperidyl benzilate;  
128 (cc) Psilocybin;  
129 (dd) Psilocyn;
- 130 (ee) Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis  
131 (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis  
132 plant, or in the resinous extractives of such plant, or synthetic substances, derivatives, and their  
133 isomers with similar chemical structure and pharmacological activity to those substances  
134 contained in the plant, such as the following:
- 135 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;  
136 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;  
137 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;  
138 d. Any compounds of these structures, regardless of numerical designation of atomic  
139 positions covered;
- 140 (ff) Ethylamine analog of phencyclidine;  
141 (gg) Pyrrolidine analog of phencyclidine;  
142 (hh) Thiophene analog of phencyclidine;  
143 (ii) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;  
144 (jj) Salvia divinorum;  
145 (kk) Salvinorin A;  
146 (ll) Synthetic cannabinoids:
- 147 a. Any compound structurally derived from 3-(1-naphthoyl)indole or  
148 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by  
149 alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl  
150 or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any  
151 extent, whether or not substituted in the naphthyl ring to any extent. Including, but not limited  
152 to:
- 153 (i) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;  
154 (ii) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;  
155 (iii) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;  
156 (iv) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;  
157 (v) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;  
158 (vi) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole;  
159 (vii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;

- 160 (viii) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole;  
161 (ix) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;  
162 (x) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;  
163 (xi) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole;  
164 (xii) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
- 165 b. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the  
166 nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
167 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further  
168 substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any  
169 extent;
- 170 c. Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution  
171 at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
172 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or  
173 not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl  
174 ring to any extent;
- 175 d. Any compound structurally derived from 3-phenylacetylindole by substitution at the  
176 nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
177 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further  
178 substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any  
179 extent. Including, but not limited to:
- 180 (i) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole;  
181 (ii) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole;  
182 (iii) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;  
183 (iv) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole;  
184 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;
- 185 e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by  
186 substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
187 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or  
188 not substituted in the cyclohexyl ring to any extent. Including, but not limited to:
- 189 (i) CP 47, 497 & homologues, or 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-  
190 2-yl)phenol), where side chain n=5, and homologues where side chain n=4,6, or 7;
- 191 f. Any compound containing a 3-(benzoyl)indole structure with substitution at the  
192 nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
193 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further  
194 substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to  
195 any extent. Including, but not limited to:

- 196 (i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;  
197 (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole;  
198 g. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-  
199 2-yl] oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;  
200 h. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-  
201 6a,7,10,10 a-tetrahydrobenzo[c]chromen-1-ol;  
202 i. HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-  
203 methyloctan-2-yl )-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;  
204 j. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]  
205 oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;  
206 k. Dimethylheptylpyran, or DMHP;  
207 (5) Any material, compound, mixture or preparation containing any quantity of the  
208 following substances having a depressant effect on the central nervous system, including their  
209 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of  
210 isomers is possible within the specific chemical designation:  
211 (a) Gamma-hydroxybutyric acid;  
212 (b) Mecloqualone;  
213 (c) Methaqualone;  
214 (6) Any material, compound, mixture or preparation containing any quantity of the  
215 following substances having a stimulant effect on the central nervous system, including their  
216 salts, isomers and salts of isomers:  
217 (a) Aminorex;  
218 (b) N-benzylpiperazine;  
219 (c) Cathinone;  
220 (d) Fenethylamine;  
221 (e) 3-Fluoromethcathinone;  
222 (f) 4-Fluoromethcathinone;  
223 (g) Mephedrone, or 4-methylmethcathinone;  
224 (h) Methcathinone;  
225 (i) 4-methoxymethcathinone;  
226 (j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);  
227 (k) Methylenedioxypropylvalerone, MDPV, or (1-(1,3-Benzodioxol-5-yl)-2-(1-  
228 pyrrolidinyl)-1-pentanone);  
229 (l) Methylone, or 3,4-Methylenedioxypropylvalerone;  
230 (m) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP;  
231 (n) N-ethylamphetamine;

- 232 (o) N,N-dimethylamphetamine;
- 233 (7) A temporary listing of substances subject to emergency scheduling under federal law
- 234 shall include any material, compound, mixture or preparation which contains any quantity of the
- 235 following substances:
- 236 (a) N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its optical isomers,
- 237 salts and salts of isomers;
- 238 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its
- 239 optical isomers, salts and salts of isomers;
- 240 (8) Khat, to include all parts of the plant presently classified botanically as *catha edulis*,
- 241 whether growing or not; the seeds thereof; any extract from any part of such plant; and every
- 242 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.
- 243 3. The department of health and senior services shall place a substance in Schedule II
- 244 if it finds that:
- 245 (1) The substance has high potential for abuse;
- 246 (2) The substance has currently accepted medical use in treatment in the United States,
- 247 or currently accepted medical use with severe restrictions; and
- 248 (3) The abuse of the substance may lead to severe psychic or physical dependence.
- 249 4. The controlled substances listed in this subsection are included in Schedule II:
- 250 (1) Any of the following substances whether produced directly or indirectly by extraction
- 251 from substances of vegetable origin, or independently by means of chemical synthesis, or by
- 252 combination of extraction and chemical synthesis:
- 253 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or
- 254 opiate, excluding apomorphine, thebaine-derived butorphanol, dextrophan, nalbuphine,
- 255 nalmefene, naloxone and naltrexone, and their respective salts but including the following:
- 256 a. Raw opium;
- 257 b. Opium extracts;
- 258 c. Opium fluid;
- 259 d. Powdered opium;
- 260 e. Granulated opium;
- 261 f. Tincture of opium;
- 262 g. Codeine;
- 263 h. Ethylmorphine;
- 264 i. Etorphine hydrochloride;
- 265 j. Hydrocodone;
- 266 k. Hydromorphone;
- 267 l. Metopon;



- 268 m. Morphine;
- 269 n. Oxycodone;
- 270 o. Oxymorphone;
- 271 p. Thebaine;
- 272 (b) Any salt, compound, derivative, or preparation thereof which is chemically
- 273 equivalent or identical with any of the substances referred to in this subdivision, but not
- 274 including the isoquinoline alkaloids of opium;
- 275 (c) Opium poppy and poppy straw;
- 276 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
- 277 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
- 278 with any of these substances, but not including decocainized coca leaves or extractions which
- 279 do not contain cocaine or ecgonine;
- 280 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid
- 281 or powder form which contains the phenanthrene alkaloids of the opium poppy);
- 282 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
- 283 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
- 284 the specific chemical designation, dextrorphan and levopropoxyphene excepted:
- 285 (a) Alfentanil;
- 286 (b) Alphaprodine;
- 287 (c) Anileridine;
- 288 (d) Bezitramide;
- 289 (e) Bulk dextropropoxyphene;
- 290 (f) Carfentanil;
- 291 (g) Dihydrocodeine;
- 292 (h) Diphenoxylate;
- 293 (i) Fentanyl;
- 294 (j) Isomethadone;
- 295 (k) Levo-alphaacetylmethadol;
- 296 (l) Levomethorphan;
- 297 (m) Levorphanol;
- 298 (n) Metazocine;
- 299 (o) Methadone;
- 300 (p) Meperidine;
- 301 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
- 302 (r) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--carboxylic
- 303 acid;

- 304 (s) Pethidine (meperidine);
- 305 (t) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 306 (u) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 307 (v) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 308 (w) Phenazocine;
- 309 (x) Piminodine;
- 310 (y) Racemethorphan;
- 311 (z) Racemorphan;
- 312 (aa) Remifentanyl;
- 313 (bb) Sufentanyl;
- 314 (cc) Tapentadol;
- 315 (3) Any material, compound, mixture, or preparation which contains any quantity of the
- 316 following substances having a stimulant effect on the central nervous system:
- 317 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 318 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
- 319 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
- 320 (d) Phenmetrazine and its salts;
- 321 (e) Methylphenidate;
- 322 (4) Any material, compound, mixture, or preparation which contains any quantity of the
- 323 following substances having a depressant effect on the central nervous system, including its salts,
- 324 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers
- 325 is possible within the specific chemical designation:
- 326 (a) Amobarbital;
- 327 (b) Glutethimide;
- 328 (c) Pentobarbital;
- 329 (d) Phencyclidine;
- 330 (e) Secobarbital;
- 331 (5) Any material or compound which contains any quantity of nabilone;
- 332 (6) Any material, compound, mixture, or preparation which contains any quantity of the
- 333 following substances:
- 334 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;
- 335 (b) Immediate precursors to phencyclidine (PCP):
- 336 a. 1-phenylcyclohexylamine;
- 337 b. 1-piperidinocyclohexanecarbonitrile (PCC);
- 338 (7) Any material, compound, mixture, or preparation which contains any quantity of the
- 339 following alkyl nitrites:

340 (a) Amyl nitrite;

341 (b) Butyl nitrite.

342 5. The department of health and senior services shall place a substance in Schedule III  
343 if it finds that:

344 (1) The substance has a potential for abuse less than the substances listed in Schedules  
345 I and II;

346 (2) The substance has currently accepted medical use in treatment in the United States;  
347 and

348 (3) Abuse of the substance may lead to moderate or low physical dependence or high  
349 psychological dependence.

350 6. The controlled substances listed in this subsection are included in Schedule III:

351 (1) Any material, compound, mixture, or preparation which contains any quantity of the  
352 following substances having a potential for abuse associated with a stimulant effect on the  
353 central nervous system:

354 (a) Benzphetamine;

355 (b) Chlorphentermine;

356 (c) Clortermine;

357 (d) Phendimetrazine;

358 (2) Any material, compound, mixture or preparation which contains any quantity or salt  
359 of the following substances or salts having a depressant effect on the central nervous system:

360 (a) Any material, compound, mixture or preparation which contains any quantity or salt  
361 of the following substances combined with one or more active medicinal ingredients:

362 a. Amobarbital;

363 b. Secobarbital;

364 c. Pentobarbital;

365 (b) Any suppository dosage form containing any quantity or salt of the following:

366 a. Amobarbital;

367 b. Secobarbital;

368 c. Pentobarbital;

369 (c) Any substance which contains any quantity of a derivative of barbituric acid or its  
370 salt;

371 (d) Chlorhexadol;

372 (e) Embutramide;

373 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in  
374 a drug product for which an application has been approved under Section 505 of the federal  
375 Food, Drug, and Cosmetic Act;

- 376 (g) Ketamine, its salts, isomers, and salts of isomers;  
377 (h) Lysergic acid;  
378 (i) Lysergic acid amide;  
379 (j) Methyprylon;  
380 (k) Sulfondiethylmethane;  
381 (l) Sulfonethylmethane;  
382 (m) Sulfonmethane;  
383 (n) Tiletamine and zolazepam or any salt thereof;  
384 (3) Nalorphine;  
385 (4) Any material, compound, mixture, or preparation containing limited quantities of any  
386 of the following narcotic drugs or their salts:  
387 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than  
388 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid  
389 of opium;  
390 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than  
391 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized  
392 therapeutic amounts;  
393 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters  
394 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an  
395 isoquinoline alkaloid of opium;  
396 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters  
397 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic  
398 ingredients in recognized therapeutic amounts;  
399 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more  
400 than ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in  
401 recognized therapeutic amounts;  
402 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters  
403 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic  
404 ingredients in recognized therapeutic amounts;  
405 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per  
406 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more  
407 active nonnarcotic ingredients in recognized therapeutic amounts;  
408 (h) Not more than fifty milligrams of morphine per one hundred milliliters or per one  
409 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic  
410 amounts;

411 (5) Any material, compound, mixture, or preparation containing any of the following  
412 narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;

413 (6) Anabolic steroids. Any drug or hormonal substance, chemically and  
414 pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and  
415 dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is  
416 expressly intended for administration through implants to cattle or other nonhuman species and  
417 which has been approved by the Secretary of Health and Human Services for that administration.  
418 If any person prescribes, dispenses, or distributes such steroid for human use, such person shall  
419 be considered to have prescribed, dispensed, or distributed an anabolic steroid within the  
420 meaning of this subdivision. Unless specifically excepted or unless listed in another schedule,  
421 any material, compound, mixture or preparation containing any quantity of the following  
422 substances, including its salts, esters and ethers:

- 423 (a) 3 $\beta$ ,17-dihydroxy-5 $\alpha$ -androstane;
- 424 (b) 3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane;
- 425 (c) 5 $\alpha$ -androstan-3,17-dione;
- 426 (d) 1-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androst-1-ene);
- 427 (e) 1-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androst-1-ene);
- 428 (f) 4-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxy-androst-4-ene);
- 429 (g) 5-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxy-androst-5-ene);
- 430 (h) 1-androstenedione ([5 $\alpha$ ]-androst-1-en-3,17-dione);
- 431 (i) 4-androstenedione (androst-4-en-3,17-dione);
- 432 (j) 5-androstenedione (androst-5-en-3,17-dione);
- 433 (k) Bolasterone (7 $\alpha$ , 17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyandrost-4-en-3-one);
- 434 (l) Boldenone (17 $\beta$ -hydroxyandrost-1,4,-diene-3-one);
- 435 (m) Boldione;
- 436 (n) Calusterone (7 $\beta$ , 17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyandrost-4-en-3-one);
- 437 (o) Clostebol (4-chloro-17 $\beta$ -hydroxyandrost-4-en-3-one);
- 438 (p) Dehydrochloromethyltestosterone (4-chloro-17 $\beta$ -hydroxy-17 $\alpha$ -methyl-androst-1,  
439 4-dien-3-one);
- 440 (q) Desoxymethyltestosterone;
- 441 (r) ?1-dihydrotestosterone (a.k.a. '1-testosterone')(17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one);
- 442 (s) 4-dihydrotestosterone (17 $\beta$ -hydroxy-androstan-3-one);
- 443 (t) Drostanolone (17 $\beta$ -hydroxy-2 $\alpha$ -methyl-5 $\alpha$ -androstan-3-one);
- 444 (u) Ethylestrenol (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-ene);
- 445 (v) Fluoxymesterone (9-fluoro-17 $\alpha$ -methyl-11 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-en-3-one);
- 446 (w) Formebolone (2-formyl-17 $\alpha$ -methyl-11 $\alpha$ ,17 $\beta$ -dihydroxyandrost-1,4-dien-3-one);

- 447 (x) Furazabol (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrostano[2,3-c]-furan);  
448 (y) 13 $\beta$ -ethyl-17 $\beta$ -hydroxygon-4-en-3-one;  
449 (z) 4-hydroxytestosterone (4,17 $\beta$ -dihydroxy-androst-4-en-3-one);  
450 (aa) 4-hydroxy-19-nortestosterone (4,17 $\beta$ -dihydroxy-estr-4-en-3-one);  
451 (bb) Mestanolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-5-androstan-3-one);  
452 (cc) Mesterolone (1 $\alpha$ -methyl-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androstan-3-one);  
453 (dd) Methandienone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-1,4-dien-3-one);  
454 (ee) Methandriol (17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-5-ene);  
455 (ff) Methenolone (1-methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one);  
456 (gg) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane);  
457 (hh) 17 $\alpha$ -methyl-3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane);  
458 (ii) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-ene;  
459 (jj) 17 $\alpha$ -methyl-4-hydroxynandrolone (17 $\alpha$ -methyl-4-hydroxy-17 $\beta$ -hydroxyestr-4-en-  
460 3-one);  
461 (kk) Methyldienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9(10)-dien-3-one);  
462 (ll) Methyltrienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9-11-trien-3-one);  
463 (mm) Methyltestosterone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-4-en-3-one);  
464 (nn) Mibolerone (7 $\alpha$ ,17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyestr-4-en-3-one);  
465 (oo) 17 $\alpha$ -methyl-?1-dihydrotestosterone (17 $\beta$ -hydroxy-17 $\alpha$ -methyl-5 $\alpha$ -androst-1-en-  
466 3-one) (a.k.a. '17 $\alpha$ -methyl-1-testosterone');  
467 (pp) Nandrolone (17 $\beta$ -hydroxyestr-4-ene-3-one);  
468 (qq) 19-nor-4-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-4-ene);  
469 (rr) 19-nor-4-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-4-ene);  
470 (ss) 19-nor-4,9(10)-androstadienedione;  
471 (tt) 19-nor-5-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-5-ene);  
472 (uu) 19-nor-5-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-5-ene);  
473 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);  
474 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);  
475 (xx) Norbolethone (13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-4-en-3-one);  
476 (yy) Norclostebol (4-chloro-17 $\beta$ -hydroxyestr-4-en-3-one);  
477 (zz) Norethandrolone (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-en-3-one);  
478 (aaa) Normethandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestr-4-en-3-one);  
479 (bbb) Oxandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-2-oxa-[5 $\alpha$ ]-androstan-3-one);  
480 (ccc) Oxymesterone (17 $\alpha$ -methyl-4,17 $\beta$ -dihydroxyandrost-4-en-3-one);  
481 (ddd) Oxymethalone (17 $\alpha$ -methyl-2-hydroxymethylene-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androstan-  
482 3-one);

- 483 (eee) Stanozolol (17a-methyl-17 $\beta$ -hydroxy-[5a]-androst-2-eno[3,2-c]-pyrazole);  
484 (fff) Stenbolone (17 $\beta$ -hydroxy-2-methyl-[5a]-androst-1-en-3-one);  
485 (ggg) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);  
486 (hhh) Testosterone (17 $\beta$ -hydroxyandrost-4-en-3-one);  
487 (iii) Tetrahydrogestrinone (13 $\beta$ ,17a-diethyl-17 $\beta$ -hydroxygon-4,9,11-trien-3-one);  
488 (jjj) Trenbolone (17 $\beta$ -hydroxyestr-4,9,11-trien-3-one);  
489 (kkk) Any salt, ester, or ether of a drug or substance described or listed in this  
490 subdivision, except an anabolic steroid which is expressly intended for administration through  
491 implants to cattle or other nonhuman species and which has been approved by the Secretary of  
492 Health and Human Services for that administration;
- 493 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a  
494 United States Food and Drug Administration approved drug product;
- 495 (8) The department of health and senior services may except by rule any compound,  
496 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions  
497 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to  
498 195.320 if the compound, mixture, or preparation contains one or more active medicinal  
499 ingredients not having a stimulant or depressant effect on the central nervous system, and if the  
500 admixtures are included therein in combinations, quantity, proportion, or concentration that  
501 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on  
502 the central nervous system.
- 503 7. The department of health and senior services shall place a substance in Schedule IV  
504 if it finds that:
- 505 (1) The substance has a low potential for abuse relative to substances in Schedule III;  
506 (2) The substance has currently accepted medical use in treatment in the United States;  
507 and
- 508 (3) Abuse of the substance may lead to limited physical dependence or psychological  
509 dependence relative to the substances in Schedule III.
- 510 8. The controlled substances listed in this subsection are included in Schedule IV:
- 511 (1) Any material, compound, mixture, or preparation containing any of the following  
512 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities  
513 as set forth below:
- 514 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms  
515 of atropine sulfate per dosage unit;
- 516 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-  
517 propionoxybutane);

518 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall  
519 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer  
520 upon the compound, mixture or preparation valuable medicinal qualities other than those  
521 possessed by the narcotic drug alone:

522 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per  
523 one hundred grams;

524 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters  
525 or per one hundred grams;

526 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters  
527 or per one hundred grams;

528 (2) Any material, compound, mixture or preparation containing any quantity of the  
529 following substances, including their salts, isomers, and salts of isomers whenever the existence  
530 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

531 (a) Alprazolam;

532 (b) Barbitol;

533 (c) Bromazepam;

534 (d) Camazepam;

535 (e) Chloral betaine;

536 (f) Chloral hydrate;

537 (g) Chlordiazepoxide;

538 (h) Clobazam;

539 (i) Clonazepam;

540 (j) Clorazepate;

541 (k) Clotiazepam;

542 (l) Cloxazolam;

543 (m) Delorazepam;

544 (n) Diazepam;

545 (o) Dichloralphenazone;

546 (p) Estazolam;

547 (q) Ethchlorvynol;

548 (r) Ethinamate;

549 (s) Ethyl loflazepate;

550 (t) Fludiazepam;

551 (u) Flunitrazepam;

552 (v) Flurazepam;

553 (w) Fospropofol;



- 554 (x) Halazepam;  
555 (y) Haloxazolam;  
556 (z) Ketazolam;  
557 (aa) Loprazolam;  
558 (bb) Lorazepam;  
559 (cc) Lormetazepam;  
560 (dd) Mebutamate;  
561 (ee) Medazepam;  
562 (ff) Meprobamate;  
563 (gg) Methohexital;  
564 (hh) Methylphenobarbital (mephobarbital);  
565 (ii) Midazolam;  
566 (jj) Nimetazepam;  
567 (kk) Nitrazepam;  
568 (ll) Nordiazepam;  
569 (mm) Oxazepam;  
570 (nn) Oxazolam;  
571 (oo) Paraldehyde;  
572 (pp) Petrichloral;  
573 (qq) Phenobarbital;  
574 (rr) Pinazepam;  
575 (ss) Prazepam;  
576 (tt) Quazepam;  
577 (uu) Temazepam;  
578 (vv) Tetrazepam;  
579 (ww) Triazolam;  
580 (xx) Zaleplon;  
581 (yy) Zolpidem;  
582 (zz) Zopiclone;  
583 (3) Any material, compound, mixture, or preparation which contains any quantity of the  
584 following substance including its salts, isomers and salts of isomers whenever the existence of  
585 such salts, isomers and salts of isomers is possible: fenfluramine;  
586 (4) Any material, compound, mixture or preparation containing any quantity of the  
587 following substances having a stimulant effect on the central nervous system, including their  
588 salts, isomers and salts of isomers:  
589 (a) Cathine ((+)-norpseudoephedrine);

- 590 (b) Diethylpropion;  
591 (c) Fencamfamin;  
592 (d) Fenproporex;  
593 (e) Mazindol;  
594 (f) Mefenorex;  
595 (g) Modafinil;  
596 (h) Pemoline, including organometallic complexes and chelates thereof;  
597 (i) Phentermine;  
598 (j) Pipradrol;  
599 (k) Sibutramine;  
600 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);  
601 (5) Any material, compound, mixture or preparation containing any quantity of the  
602 following substance, including its salts:  
603 (a) butorphanol;  
604 (b) pentazocine;  
605 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance  
606 is the only active medicinal ingredient;  
607 (7) The department of health and senior services may except by rule any compound,  
608 mixture, or preparation containing any depressant substance listed in subdivision (1) of this  
609 subsection from the application of all or any part of sections 195.010 to 195.320 and sections  
610 579.015 to 579.086 if the compound, mixture, or preparation contains one or more active  
611 medicinal ingredients not having a depressant effect on the central nervous system, and if the  
612 admixtures are included therein in combinations, quantity, proportion, or concentration that  
613 vitiate the potential for abuse of the substances which have a depressant effect on the central  
614 nervous system.
- 615 9. The department of health and senior services shall place a substance in Schedule V  
616 if it finds that:
- 617 (1) The substance has low potential for abuse relative to the controlled substances listed  
618 in Schedule IV;
- 619 (2) The substance has currently accepted medical use in treatment in the United States;  
620 and
- 621 (3) The substance has limited physical dependence or psychological dependence liability  
622 relative to the controlled substances listed in Schedule IV.
- 623 10. The controlled substances listed in this subsection are included in Schedule V:
- 624 (1) Any compound, mixture or preparation containing any of the following narcotic  
625 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set

626 forth below, which also contains one or more nonnarcotic active medicinal ingredients in  
627 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal  
628 qualities other than those possessed by the narcotic drug alone:

629 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than  
630 twenty-five micrograms of atropine sulfate per dosage unit;

631 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per  
632 one hundred grams;

633 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five  
634 micrograms of atropine sulfate per dosage unit;

635 (2) Any material, compound, mixture or preparation which contains any quantity of the  
636 following substance having a stimulant effect on the central nervous system including its salts,  
637 isomers and salts of isomers: pyrovalerone;

638 (3) Any compound, mixture, or preparation containing any detectable quantity of  
639 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,  
640 mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical  
641 isomers, or salts of optical isomers;

642 (4) Unless specifically exempted or excluded or unless listed in another schedule, any  
643 material, compound, mixture, or preparation which contains any quantity of the following  
644 substances having a depressant effect on the central nervous system, including its salts:

645 (a) Lacosamide;

646 (b) Pregabalin.

647 11. If any compound, mixture, or preparation as specified in subdivision (3) of  
648 subsection 10 of this section is dispensed, sold, or distributed in a pharmacy without a  
649 prescription:

650 (1) All packages of any compound, mixture, or preparation containing any detectable  
651 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine,  
652 its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind  
653 a pharmacy counter where the public is not permitted, and only by a registered pharmacist or  
654 registered pharmacy technician; and

655 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,  
656 or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers,  
657 or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers  
658 shall be at least eighteen years of age; and

659 (3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require  
660 any person, prior to such person's purchasing, receiving or otherwise acquiring such compound,  
661 mixture, or preparation to furnish suitable photo identification that is issued by a state or the

662 federal government or a document that, with respect to identification, is considered acceptable  
663 and showing the date of birth of the person;

664 (4) The seller shall deliver the product directly into the custody of the purchaser.

665 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall  
666 implement and maintain an electronic log of each transaction. Such log shall include the  
667 following information:

668 (1) The name, address, and signature of the purchaser;

669 (2) The amount of the compound, mixture, or preparation purchased;

670 (3) The date and time of each purchase; and

671 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy  
672 technician who dispensed the compound, mixture, or preparation to the purchaser.

673 13. Each pharmacy shall submit information regarding sales of any compound, mixture,  
674 or preparation as specified in subdivision (3) of subsection 10 of this section in accordance with  
675 transmission methods and frequency established by the department by regulation;

676 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities  
677 greater than those specified in this chapter.

678 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products  
679 in a pharmacy shall ensure that all such products are located only behind a pharmacy counter  
680 where the public is not permitted.

681 16. The penalties for a knowing or reckless violation of the provisions of subsections 11  
682 to 15 of this section are found in section 579.060.

683 17. The scheduling of substances specified in subdivision (3) of subsection 10 of this  
684 section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds,  
685 mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound,  
686 mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must  
687 be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.

688 18. The manufacturer of a drug product or another interested party may apply with the  
689 department of health and senior services for an exemption from this section. The department of  
690 health and senior services may grant an exemption by rule from this section if the department  
691 finds the drug product is not used in the illegal manufacture of methamphetamine or other  
692 controlled or dangerous substances. The department of health and senior services shall rely on  
693 reports from law enforcement and law enforcement evidentiary laboratories in determining if the  
694 proposed product can be used to manufacture illicit controlled substances.

695 19. The department of health and senior services shall revise and republish the schedules  
696 annually.

697           20. The department of health and senior services shall promulgate rules under chapter  
698 536 regarding the security and storage of Schedule V controlled substances, as described in  
699 subdivision (3) of subsection 10 of this section, for distributors as registered by the department  
700 of health and senior services.

701           21. Logs of transactions required to be kept and maintained by this section and section  
702 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is  
703 the person whose transactions are recorded in the logs.

704           **22. Beginning January 1, 2017, the director of the department of health and senior**  
705 **services shall notify the revisor of statutes of any controlled substances that are added or**  
706 **removed from the five schedules of controlled substances established by the federal**  
707 **Controlled Substances Act under 21 U.S.C. section 801, et seq. The revisor shall change**  
708 **the statutory schedule of controlled substances listed in this section to include such**  
709 **additions or deletions.**

✓